Single-donor platelet concentrate, HLA and/or HPA compatible

Code 'Blood Service'

Cfr. original product sheet

NIHDI Code

Hospitalized: 752 522

Non-hospitalized: 752 511

Thrombopenia in patients with antibodies to HLA or HPA antigens. In neonates with severe thrombopenia due to maternal HPA antibodies (neonatal allo-immune thrombopenia, NAIT), platelets negative for the relevant HPA antigen are administered preventively if possible. HLA- or HPA-compatible single-donor platelets are also indicated in immunologic refractoriness due to anti-HLA and/or anti-HPA antibodies, either prophylactically or when bleeding occurs, depending on the severity of thrombopenia.

Het gebruik van bloedplaatjesconcentraten is gecontra-indiceerd bij patiënten met een voorgeschiedenis van allergische reacties op amotosalen of psoralenen. Bloedplaatjesconcentraten dienen niet te worden voorgeschreven aan neonatale patiënten die behandeld zij met fototherapie-apparaten die een piekgolflengte van minder dan 425 nm afgeven, en/of een lagere limiet van de emissiebandbreedte van <375 nm hebben. 

Donor platelets can be compatible with the recipient in three ways (in descending degree of compatibility): 1. the same HLA antigens in donor and recipient (HLA-identical); 2. the donor is negative for the antigens for which the recipient is negative (HLA-matched); 3. negative for the antigens against which the recipient has HLA and/or HPA antibodies (mismatch, but compatible in the narrow sense). Compatible donors or products are selected by the Central Laboratory for Histocompatibility and Immunogenetics (HILA) at Blood Service.

Platelets are preferably administered ABO compatible; for small children and in repeated transfusions, ABO compatibility of the plasma is also important and ABO-identical platelets are recommended. With HLA- or HPA-type platelets, however, this is not always possible. In these cases, one must be aware during transfusion of the possibility of hemolysis due to plasma incompatibility (hemolysins anti-A or anti-B). However, given that these platelets are resuspended in a mixture of serum and storage fluid, and single-donor platelet concentrates are tested for high titers of hemolysins, a severe hemolytic reaction is not to be expected. This risk must be weighed against the need to obtain a better yield from platelet transfusion.

Resus D-negative female recipients younger than 50 years of age are preferably treated with platelets from resus D-negative donors. If platelets from rhesus D-positive donors are still used for these patients, rhesus D immunization should be prevented by administration of anti-resus D immunoglobulins.

By medical prescription after ordering at least 3 business days in advance subject to availability of compatible donors.